MMR vaccine - Berna Biotech

Drug Profile

MMR vaccine - Berna Biotech

Alternative Names: Measles-mumps-rubella-vaccine-Berna Biotech

Latest Information Update: 03 Jun 2010

Price : $50

At a glance

  • Originator Berna Biotech
  • Class Measles vaccines; Rubella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Measles; Mumps; Rubella

Most Recent Events

  • 30 Nov 2003 Phase-III clinical trials in Rubella in Switzerland (Injection)
  • 30 Nov 2003 Phase-III clinical trials in Mumps in Switzerland (Injection)
  • 30 Nov 2003 Phase-III clinical trials in Measles in Switzerland (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top